CoChat

The muscarinic M5 receptor: a silent or emerging subtype?

Open access
Eglen, R M, Nahorski, S R · 2000 · British Journal of Pharmacology
Cited by 120

The DOI matches its Crossref record.

Abstract

The muscarinic acetylcholine receptors belong to the super-family of seven TM domain receptors that interact with G-proteins to initiate intracellular responses. Evidence from molecular cloning indicates that there are separate intronless human genes that encode five muscarinic receptor glycoproteins. Muscarinic receptor sequences have significant homologies with other members of this large super-family and the genes are very similar across mammalian species (Caulfield 1993; Felder 1995). Despite over a decade following their molecular identification, the therapeutic exploitation of this crucial family of receptors remains disappointing. This results from a relative inability to pharmacologically distinguish between the subtypes, markedly hindering their investigation in native mammalian tissues. In particular, this has hampered investigation of the last-identified subtype, the muscarinic M5 receptor. The inability to clearly distinguish it from the M3 receptor has, moreover, led to confusion of its physiological role. Finally, determination of the precise distribution of M5 receptors within tissues is complicated by inadequate selectivity of radioligands as well as the low sensitivity/selectivity of polyclonal antisera in immunocytochemical studies (Caulfield 1993; Reever et al., 1997). Despite these problems, this receptor has recently been assigned an upper case M5 nomenclature (Caulfield & Birdsall, 1998) presumably reflecting recognition of its presence and function in native tissues despite the current incomplete characterization. In this respect the identification of a human A2058 melanoma cell that endogenously expresses the M5 receptor (Kohn et al., 1996) should facilitate its investigation in endogenous tissues, although extensive use of these cells have not been reported to date. Consequently, the majority of the current information on the functional properties and regulation of coupling of this subtype still arises from their expression in model cells following cDNA transfection. The purpose of this short review is to critically evaluate current data on the muscarinic receptor M5 subtype from several standpoints. Hopefully, this critique will stimulate further studies on the M5 receptor that may raise it from a 'relatively ephemeral' or 'fact or fiction' status, described in recent reviews (Reever et al., 1997; Caulfield & Birdsall 1998). The muscarinic M5 receptor was the last of the muscarinic receptor family to be cloned in the human and is mapped to chromosome 15q26 (Bonner et al., 1988; Liao et al., 1989). The receptor sequence conforms to a predicted seven transmembrane glycoprotein consisting of 531 residues in the human (GeneBank accession number PO8912) and 532 in the mouse (PO8911; 89% homologous to human). Structurally, the M5 receptor is the next largest muscarinic receptor to the M3 subtype with both these subtypes possessing a large third intracellular loop. Differences in this cytoplasmic loop account for the sequence diversity between muscarinic receptor subtypes and also between muscarinic receptors from different species. However, of the five muscarinic receptors, the M5 subtype demonstrates the least homology in this region when comparisons are made between human and rat sequences. Wess and colleagues (Wess et al., 1992; Pittel & Wess, 1994; Wess, 1997) have explored the nature of ligand binding and G-protein coupling by using chimeras of muscarinic M2 and M5 receptors. Most M2/M5 constructs are inactive but the presence of the M2 sequence in TMVII and M5 in TMI agonist activation of G-protein coupling is restored. Pittel & Wess (1994) argued that these data supported the bacteriorhodopsin model in which the seven transmembrane helices are arranged in a ring, such that TMI is adjacent to TMVII. A series of M2/M5 chimeras in which regions of the M5 receptors have been systemically replaced by homologous regions of the M2 receptor, indicated the higher affinity of the antagonist UH-AH 37 for the M2 over the M5 receptor was dependent upon a short stretch of 31 residues in TMVI as well as a short region of the third intracellular loop. This however contrasts to the antagonist AQ-RA 741 which also preferentially binds to the M2 receptor suggesting that different receptor epitopes may be involved in conferring different ligand specificities. In a series of studies, Brann and colleagues also attempted to identify key residues associated with agonist activation of M5 receptors. Initially using random saturation mutagenesis they identified the amino acids 439, A440, A441 towards the C-terminal end of the third intracellular loop of the M5 muscarinic receptor critical for G-protein coupling (Burstein et al., 1995). In a more recent paper, this group (Burstein et al., 1998a) constructed a further series of point mutants at each of these residues and characterized their functional phenotypes in order to find structure function relationship for G-protein coupling to the M5 receptor. Their

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0703276

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 120

Metadata

Authors
Eglen, R. M., & Nahorski, S. R.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2000-05
Volume
130
Issue
1
Pages
13-21
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2148096761
Cited by
120
References
0
FWCI
3.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The muscarinic M5 receptor: a silent or emerging subtype? https://app.cochat.ai/papers/10.1038/sj.bjp.0703276
The paper
Eglen, R. M., & Nahorski, S. R. (2000). The muscarinic M5 receptor: a silent or emerging subtype? British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0703276

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.